Regorafenib data at the 2012 ASCO-GI Congress
January 19 - 21, 2012
San Francisco, CA, U.S.
Results from the Phase III CORRECT study with regorafenib in patients with metastatic colorectal cancer were presented as a late breaking abstract in an oral abstract session on January 21 (2:30 PM - 4:00 PM Pacific Time) at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA, U.S. On this occasion we held a conference call for investors and analysts.
Positive Phase III Data on Bayer's Investigational Drug Regorafenib Show Significant Increase in Overall SurvivalFirst presentation of data from CORRECT trial as "Late Breaking Abstract" at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) more
Monday, January 23, 2012 at approx. 12:30 p.m. CET (11:30 a.m. GMT): Investor Conference Call on Regorafenib
Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Jörg Möller, Head of Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations